Tag Archives: market

Why Market Vectors China ETF Is Different

NEW YORK (ETF Expert) — Plenty of retail investors as well as institutional money managers weren’t able to get IPO shares of Facebook at $ 38 per share.

Their initial disappointment stemmed from expectations that Facebook would finish Friday with a 20% gain around $ 45 or $ 46.

Yet the ability to get in on something — even a “sure thing” — isn’t always what it is cracked up to be. On Monday, Facebook shares traded around $ 33 to $ 34, or 10% below the coveted offer price. …

Click to view a price quote on PEK.

Click to research the Financial Services industry.

Market Wrap-Up for May 21 (FB, LOW, CPB, BA, CAT, HON, more)

It was a snap-back Monday for the U.S. averages, as traders dug their heels in and bought their share of high-beta stocks that have been hit hard this past month. I certainly don’t miss the days of waiting for those bounces, whenever I let my trading discipline down (which happened less and less after learning some crucial early lessons).

Looking at today’s action, the bounce did not help the earnings stories of Lowe’s (LOW) and Campbell Soup (CPB). On the flipside, positive analyst commentary helped lift stocks like American Eagle Outfitters (AEO) and Boeing (BA). Commodity/Capital goods plays like Caterpillar (CAT), Deere (DE), and Honeywell (HON) also regained a bit of their losses from the past month or so. It’s too early to tell if today marks any significant bottom for the averages, but I have more thoughts on what investors should be contemplating at this stage of the game below.

Life After Facebook IPO

As Facebook (FB) shares fell (down 12% by the close) and business commentators backpedal about what went wrong with the IPO, life for dividend investors simply proceeds as normal. The pomp and circumstance of the IPO has passed and retail investors who bought the stock are likely wondering, do I buy more, or do I sit pat? Most won’t think about selling at a loss, because human nature makes it very hard for inexperienced investors to accept bad trades/losses.

The business media is frantically trying to make sense of Facebook’s early price weakness. Of course, the media won’t look at itself for making retail investors foam at the mouth about the IPO in the first place. Instead, they’re blaming Wall Street, the underwriters, or the Nasdaq exchange itself for having trade execution issues. Smart dividend investors will look back on this story as just another lesson to keep in mind when they’re tempted to roll the dice on a hot new “can’t-miss” IPO.

Following the recent wider market pullback, we continue to look for more dividend opportunities. All the while, we’re closely watching our current picks to see if they still warrant new investing capital. If we see danger signs for the business of one of the stocks we recommend, we will not hesitate to say “sell” altogether (although most of our downgrades are simply “holds”).

Dividends Still Don’t Lie: The Truth About Investing in Blue Chip Stocks and Winning in the Stock Market

Dividends Still Don’t Lie: The Truth About Investing in Blue Chip Stocks and Winning in the Stock Market

Dividends Still Don't Lie: The Truth About Investing in Blue Chip Stocks and Winning in the Stock Market

A timely follow-up to the bestselling classic Dividends Don’t LieIn 1988 Geraldine Weiss wrote the classic Dividends Don’t Lie, which focused on the Dividend-Yield Theory as a method of producing consistent gains in the stock market. Today, the approach of using the dividend yield to identify values in blue chip stocks still outperforms most investment methods on a risk-adjusted basis.Written by Kelley Wright, Managing Editor of Investment Quality Trends, with a new Foreword by Geraldine Weiss,

List Price: $ 29.95

Minyanville’s T3 Weekly Recap: Facebook IPO Flop Drags Market to Fresh Lows

There was not much to "like" today about Facebook's (FB) IPO. The most hyped IPO of all time was a historic flop Friday as Zuckerberg's baby fell flat on its face closing just above the $ 38 IPO price (and only held that level because the underwriters stepped in to support it there). Excess supply and an astronomical IPO valuation took any potential juice out of the trade for retail traders and the Nasdaq essentially broke since it was unprepared for the massive volume of Facebook. The stock easily set the record for shares traded of a new issue. Facebook bottomed
Minyanville.com – All Articles

FACEPLANT: Facebook (FB) IPO Flop Pushes Market to Fresh Lows

There was not much to ‘Like” today about Facebook (http://facebook.com)’s (FB) IPO (http://en.wikipedia.org/wiki/Initial_public_offering). The most hyped IPO of all-time was a historic flop Friday as Zuckerberg (http://en.wikipedia.org/wiki/Zuckerberg)’s baby fell flat on its face. Excess supply and an astronomical IPO valuation took any potential juice out of the trade for retail traders, and the Nasdaq (http://www.nasdaq.com/) essentially broke is it was unprepared for the massive volume of FB. The stock easily set the record for shares traded of a new issue.

FB bottomed out at the IPO price, $ 38 in the first half hour of its public life, and bounced back to the price it opened for trading ($ 42.05). After that, it looked like the ship had been righted. However, after consolidating…
T3 Live

Bad News for the Mobile-Phone Market

But good news for the smartphone market.
Fool.com: The Motley Fool

Buzz on the Street: Facebook Comes to Town and Fails to Save the Day for an Exhausted Market

All day and every day some of the stock market's best and brightest traders and money managers share their ideas insights and analysis in real-time on Minyanville's Buzz & Banter. Below are some excerpts from this week's Buzz. Click here for a 14 day free trial. Note: Some links may require Buzz subscriptions. Monday May 14 2012 Bond Tally Fil Zucchi Please do not bother corporate bond buyers with minutia like an entire continent on the verge of financial anarchy. As of this writing a couple of issuers increased their offerings so that buyers could suck down $ 3.75b of new
Minyanville.com – All Articles

Double Diagonal: An Option Strategy for a Range-Bound Market

MINYANVILLE ORIGINAL While the market has definitely pulled back over the past two weeks the bears can’t seem to gain any real control as the S&P 500 Index (^GSPC) has basically settled along the 1350 fulcrum level over the past few days. At the moment investors seem paralyzed by opposing forces. On one side we have attractive fundamentals in which corporations are delivering healthy profits and valuations are attractive especially relative to near-zero interest rates. On the other hand the triumvirate of the euro mess a sluggish employment picture and evidence of a slowdown in the emerging markets has many
Minyanville.com – All Articles

Market Wrap-Up for May 15 (HD, DKS, TJX, CL, JPM, AVP, more)

Market watchers were hoping to see a bit of the ol’ “Turnaround Tuesday” action that sometimes happens after a weak Monday session, but the bulk of the rally failed to hold by the close. The European markets spent another day in the red.

Looking at today’s market movers, retailers Dick’s Sporting Goods (DKS) (earnings report here) and TJX Companies (TJX) (read more) saw share prices pop on better-than-expected earnings results. Meanwhile, home improvement giant Home Depot (HD) ended down following its own tepid earnings numbers.

In the M&A soap opera that is Avon Products (AVP)/Coty, the latest bit of news is that Coty has withdrawn its takeover offer, less than 24 hours after Avon finally said they would consider it. Talk about bizarre! If you’ll remember, Avon rebuffed Coty’s first advance back in April, after which Coty sweetened the deal. Nonetheless, Avon shares closed down 10% on the latest news.

JP Morgan (JPM) shares squeaked out a gain as financial sector watchers were hoping to see some stability kick in following its recent drubbing. You can bet that the fallout surrounding its recent $ 2 billion trading loss is far from over.

Elsewhere, Colgate-Palmolive (CL) shares traded higher following a Wall Street analyst upgrade this morning. Clorox (CLX) shares ended flat despite news of a dividend payout hike. Be sure to check out Dividend.com premium each afternoon when we post our regular “dividend payout changes” post that breaks down all of the day’s new payouts.

The Hunger Factor

The Market is WRONG About this Big Pharma Stock

The Market is WRONG About this Big Pharma Stock

Generic prescription drugs are the bane of big pharmaceutical companies and investors alike. As patents for name brand drugs expire, generics eat into revenue, shrink earnings, and depress stock prices of the Big Pharma players.

But the smart investor knows that good drug companies are hardly one-trick ponies. The herd always overlooks the mountains of products that either still have patent protection, or have survived and retained market share. Then there's the pipeline full of new products that's often not given enough consideration.

Bottom line: It's important to be able to see the forest for the trees if you want to recognize a good investment opportunity.

And right now, industry giant AstraZeneca Plc (NYSE: AZN) is the forest. And it's on sale.

But first the not-so-good news…

The near-term picture is… well… simply "not good." In the first-quarter, sales declined 11% to $ 7.34 billion, compared with the year-ago period. Operating profits were off 19% from $ 3.67 billion reported in the first quarter of 2011. The result was a dismal 38% drop in earnings per share (EPS) from $ 2.08 to $ 1.28. It's no surprise that the company has lowered core 2012 EPS guidance from $ 6.00-$ 6.30 to $ 5.85-$ 6.15.

On top of all this, there's concern about succession at the top of management. Chairman and CEO David Brennan just announced his retirement. Chief Financial Officer Simon Lowth will serve temporarily in the top slot until a permanent replacement is found.